Patient experience data and bias — what ratings don’t tell us

28 February 2018 - Although patient-experience data are important to U.S. health care organisations, the best way to interpret them remains ...

Read more →

Using the E value to assess the potential effect of unmeasured confounding in observational studies

24 January 2019 - Randomised trials serve as the standard for comparative studies of treatment effects.  ...

Read more →

Random-effects meta-analysis: summarising evidence with caveats

22 January 2019 - Questions involving medical therapies are often studied more than once. For example, numerous clinical trials have been ...

Read more →

Patient groups fail to declare financial interests during NICE assessments

16 January 2019 - Patients’ groups involved in assessing treatments for the NHS often fail to disclose their financial interests, ...

Read more →

Challenges of non-intention-to-treat analyses

15 January 2019 - Over the past 5 decades, the randomised clinical trial has become the gold standard for evaluation ...

Read more →

Establishing the effectiveness of procedural interventions: the limited role of randomised trials

18 December 2018 - Procedural interventions comprise a large and growing component of medical care. Patients, physicians, health care organisations, and ...

Read more →

Bayesian hierarchical models

11 December 2018 - Treatment effects will differ from one study to another evaluating similar therapies, both because of random variation ...

Read more →

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

31 August 2018 - Several trials in cancer medicine over the past 5 years share two common features: first, they were ...

Read more →

Pfizer calls for FDA guidance to address false and misleading biosimilar advertisements

28 August 2018 - Taking issue with Amgen, Genentech and other reference product sponsors’ dissemination of misleading information on biosimilars, ...

Read more →

Case-control studies: using “real world” evidence to assess association

23 August 2018 - Associations between patient characteristics or treatments received and clinical outcomes are often first described using observational data, ...

Read more →

Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology

11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...

Read more →

Bias, operational bias, and generalisability in Phase II/III trials

27 June 2018 - Adaptive clinical trial designs improve the efficiency of the drug development process by allowing treatment decisions to ...

Read more →

Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany

13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...

Read more →

Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data

13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...

Read more →

Prices keep rising for drugs treating painful sex in women

3 June 2018 - For years, Lenny Hanson has watched in alarm as the price of a drug she takes ...

Read more →